Cochrane · systematic review · CD008921
Neuromodulators for pain management in rheumatoid arthritis
Richards, BL, Whittle, SL, Buchbinder, R · Cochrane Database of Systematic Reviews · 2012 · Cochrane Library
MusculoskeletalAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
9
current version
GRADE rated
9
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 8 · 88.9%Moderate 1 · 11.1%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Nefopam 60 mg tds compared to placebo for pain management in rheumatoid arthritis
Population: patients with pain management in rheumatoid arthritis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pain VAS 100mm Nefopam 60 mg tds vs placebo | no estimate extracted | 2 studies · 48 participants | Low Downgraded: risk of bias, imprecision |
Withdrawal Due to adverse events Nefopam 60 mg tds vs placebo | RR 11 [0.64, 189.65] | 1 study · 54 participants | Moderate Downgraded: imprecision |
Total adverse events Nefopam 60 mg tds vs placebo | RR 4.11 [1.58, 10.69] | 2 studies · 104 participants | Low Downgraded: risk of bias, imprecision |
Capsaicin 0.025% compared to placebo for knee pain in patients with rheumatoid arthritis
Population: patients with Knee pain in patients with rheumatoid arthritis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pain (% reduction from baseline) VAS 100mm Capsaicin 0.025% vs placebo | no estimate extracted | 1 study · 30 participants | Low Downgraded: risk of bias, imprecision |
Pain (% reduction from baseline) VAS 100mm Capsaicin 0.025% vs placebo | no estimate extracted | 1 study · 29 participants | Low Downgraded: risk of bias, imprecision |
Oromucosal cannabis (Sativex) compared to placebo for pain management in patients with rheumatoid arthritis
Population: patients with pain management in patients with rheumatoid arthritis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pain at present McGill short form questionnaire ‐ Verbal rating scale (0‐5) Oromucosal cannabis (Sativex) vs placebo | no estimate extracted | 1 study · 58 participants | Low Downgraded: risk of bias, imprecision |
Quality of Sleep Numerical rating scale (0‐10). Scale from: 0 to 10. Oromucosal cannabis (Sativex) vs placebo | no estimate extracted | 1 study · 58 participants | Low Downgraded: risk of bias, imprecision |
Withdrawal due to adverse events Oromucosal cannabis (Sativex) vs placebo | RR 0.13 [0.01, 2.39] | 1 study · 58 participants | Low Downgraded: risk of bias, imprecision |
Total adverse events Oromucosal cannabis (Sativex) vs placebo | RR 1.82 [1.1, 3] | 1 study · 58 participants | Low Downgraded: risk of bias, imprecision |